Palisade Bio, Inc. was originally established in 1996. The Company is a clinical-stage biopharmaceutical company focused on the development of next-generation once-daily oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases, and its lead drug candidate, PALI-2108, is being developed for inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. 

Palisade Bio will participate in three investor conferences in September 2026. Management will hold investor meetings at the Wells Fargo Healthcare Conference, a fireside chat at the Morgan Stanley Global Healthcare Conference, and a presentation at the H.C. Wainwright Global Investment Conference. Investors can register for live webcasts of the fireside chats on the company's website. Palisade Bio is a clinical-stage biopharmaceutical company developing prodrugs for inflammatory and fibrotic diseases, with its lead product candidate, PALI-2108, in Phase 2 clinical trials for inflammatory bowel disease.

Palisade Bio

Palisade Bio to Present at Upcoming Investor Conferences

Palisade Bio announced management participation in three healthcare investor conferences in September. The conferences include Wells Fargo 2026 Healthcare Conference, Morgan Stanley 24th Annual Global Healthcare Conference, and H.C. Wainwright 28th Annual Global Investment Conference. Investors can meet with Palisade Bio management during the conferences and webcasts of the fireside chats will be accessible on the company's website.

Palisade Bio to Present at Healthcare Conferences in September

<p>Palisade Bio reports second quarter 2026 financial results and highlights continued advancement of Pali-2108 into Phase 2 development</p>

Palisade Bio reports second quarter 2026 financial results and highlights continued advancement of Pali-2108 into Phase 2 development

<p>Palisade Bio Q2 operating income USD -11.698 million</p>

Palisade Bio Q2 operating income USD -11.698 million

Palisade Bio (PALI) shares rose 11.84% in intraday trading after Oppenheimer initiated coverage with an 'Outperform' rating and an $8 price target. The analyst initiation provides a bullish external validation for the biotechnology company, driving the current upward price movement.

PALI News